5-aminosalicylate therapy

Michael Stephens*, Alisha Michelle Mavis

*Corresponding author for this work

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Aminosalicylates are commonly used medications for the treatment of mild-to-moderate inflammatory bowel disease. The exact mechanism of action is unknown, although it is thought that aminosalicylates have more of a topical effect on the gastrointestinal mucosa rather than a systemic one. 5-ASA is a well-established first-line therapy for mild-to-moderate ulcerative colitis in the adult population, and remains an important option for children with mild-to-moderate UC. However, its use in pediatric Crohn's disease is controversial given the lack of data supporting its efficacy. Few studies have addressed the use of 5-ASA in the pediatric population. In general, aminosalicylates are well tolerated in children with few dose-related side effects. An important step forward can be expected from the NIH funded Predicting Response to Standardized Pediatric Colitis Therapy (PROTECT) Study.

Original languageEnglish (US)
Title of host publicationPediatric Inflammatory Bowel Disease, Second Edition
PublisherSpringer New York
Pages281-288
Number of pages8
ISBN (Electronic)9781461450610
ISBN (Print)9781461450603
DOIs
StatePublished - Jan 1 2013

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of '5-aminosalicylate therapy'. Together they form a unique fingerprint.

Cite this